Bio-Gene Technology Ltd (BGT) - Total Liabilities
Based on the latest financial reports, Bio-Gene Technology Ltd (BGT) has total liabilities worth AU$307.71K AUD (≈ $217.72K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Bio-Gene Technology Ltd growing its equity to track the company's year-over-year net asset growth rate.
Bio-Gene Technology Ltd - Total Liabilities Trend (2014–2025)
This chart illustrates how Bio-Gene Technology Ltd's total liabilities have evolved over time, based on quarterly financial data. See Bio-Gene Technology Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Bio-Gene Technology Ltd Competitors by Total Liabilities
The table below lists competitors of Bio-Gene Technology Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Professional Diversity Network Inc
NASDAQ:IPDN
|
USA | $6.69 Million |
|
Macarthur Minerals Ltd
AU:MIO
|
Australia | AU$1.32 Million |
|
Innovative Eyewear Inc.
NASDAQ:LUCY
|
USA | $1.11 Million |
|
21st Century Management Services Limited
NSE:21STCENMGM
|
India | Rs64.99 Million |
|
WORK Medical Technology Group LTD Ordinary Shares
NASDAQ:WOK
|
USA | $11.99 Million |
|
Sentral Mitra Informatika Tbk PT
JK:LUCK
|
Indonesia | Rp22.81 Billion |
|
Helios Energy Ltd
AU:HE8
|
Australia | AU$1.91 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Bio-Gene Technology Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bio-Gene Technology Ltd (BGT) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bio-Gene Technology Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bio-Gene Technology Ltd (2014–2025)
The table below shows the annual total liabilities of Bio-Gene Technology Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$522.98K ≈ $370.04K |
+41.94% |
| 2024-06-30 | AU$368.45K ≈ $260.70K |
-39.98% |
| 2023-06-30 | AU$613.88K ≈ $434.36K |
-40.67% |
| 2022-06-30 | AU$1.03 Million ≈ $732.10K |
+37.12% |
| 2021-06-30 | AU$754.57K ≈ $533.91K |
+33.01% |
| 2020-06-30 | AU$567.29K ≈ $401.39K |
-7.55% |
| 2019-06-30 | AU$613.61K ≈ $434.17K |
-19.22% |
| 2018-06-30 | AU$759.59K ≈ $537.46K |
+103.13% |
| 2017-06-30 | AU$373.94K ≈ $264.58K |
-2.37% |
| 2016-06-30 | AU$383.00K ≈ $271.00K |
+40004.71% |
| 2014-06-30 | AU$955.00 ≈ $675.72 |
-- |
About Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more